NVO
Europe says yes
Novo Nordisk just scored a meaningful win: the European Commission approved Wegovy in pill form, a once-daily oral semaglutide 25 mg treatment for adults with obesity or overweight plus at least one weight-related comorbidity. Translation: the company is taking its blockbuster weight-loss story and handing it a more convenient outfit.
Why investors care
This matters because convenience is the secret sauce in obesity drugs. Injections are effective, sure, but a pill is a much easier sell for a lot of patients who’d rather swallow a tablet than negotiate with a needle every week.
The approval also covers Wegovy 7.2 mg in a single-dose pen, so Novo is basically widening the doorway on both fronts:
- oral semaglutide for people who want a tablet
- a new injection option for the standard Wegovy lineup
The data behind the hype
The green light was backed by Novo’s OASIS program, including OASIS 4. In the trial, people on oral semaglutide saw about 17% weight loss versus 3% on placebo when paired with lifestyle changes. Roughly one-third of patients lost 20% or more, which is the kind of number that makes the obesity-drug market look less like a niche and more like a full-on heavyweight bout.
Safety looked broadly in line with the injectable version, with adverse event-related discontinuation at 6.9% for oral semaglutide versus 5.9% for placebo.
Bigger franchise, bigger runway
This is the fifth regulatory approval for the Wegovy pill after the U.S., U.K., U.A.E., and Bahrain. Novo says it wants to roll the treatment into more countries in the second half of 2026, which means this isn’t a one-and-done headline — it’s more like the opening lap of a wider rollout.
Big picture: Novo keeps turning GLP-1 into a platform, not just a product. And in weight loss, platform is where the big money tends to hide.